Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1994 2
1995 6
1996 4
1997 6
1998 12
1999 11
2000 12
2001 18
2002 15
2003 16
2004 32
2005 35
2006 43
2007 35
2008 46
2009 38
2010 48
2011 44
2012 43
2013 65
2014 46
2015 42
2016 40
2017 48
2018 50
2019 34
2020 24
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

729 results
Results by year
Filters applied: . Clear all
Page 1
Cytochrome P450 Structure, Function and Clinical Significance: A Review.
Manikandan P, Nagini S. Manikandan P, et al. Curr Drug Targets. 2018;19(1):38-54. doi: 10.2174/1389450118666170125144557. Curr Drug Targets. 2018. PMID: 28124606 Review.
CYP enzyme inhibition is a principal mechanism for metabolism- based drug-drug interactions. ...OBJECTIVE: The present review is a comprehensive compilation of cytochrome P450 structure, function, pharmacogenetics, pharmacoepigenetics and clinical significance. CONC
CYP enzyme inhibition is a principal mechanism for metabolism- based drug-drug interactions. ...OBJECTIVE: The present review is a co
Cytochrome P450 in Pharmacogenetics: An Update.
Tornio A, Backman JT. Tornio A, et al. Adv Pharmacol. 2018;83:3-32. doi: 10.1016/bs.apha.2018.04.007. Adv Pharmacol. 2018. PMID: 29801580 Review.
The majority of hepatically cleared drugs are metabolized by cytochrome P450 (CYP) enzymes, mainly in families CYP1, CYP2, and CYP3. Genes encoding these enzymes are highly variable with allele distribution showing considerable differences between populations. ...In this r …
The majority of hepatically cleared drugs are metabolized by cytochrome P450 (CYP) enzymes, mainly in families CYP1, CYP2, and CYP3. …
Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, Gaedigk A, Klein TE, Caudle KE, McCracken JT, de Leon J, Leeder JS. Brown JT, et al. Clin Pharmacol Ther. 2019 Jul;106(1):94-102. doi: 10.1002/cpt.1409. Epub 2019 Apr 13. Clin Pharmacol Ther. 2019. PMID: 30801677 Free PMC article. Review.
Atomoxetine is a nonstimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. ...
Atomoxetine is a nonstimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 poly …
Functional gene variants of CYP3A4.
Werk AN, Cascorbi I. Werk AN, et al. Clin Pharmacol Ther. 2014 Sep;96(3):340-8. doi: 10.1038/clpt.2014.129. Epub 2014 Jun 13. Clin Pharmacol Ther. 2014. PMID: 24926778 Review.
Cytochrome P450 3A4 (CYP3A4) is involved in the metabolism of more drugs in clinical use than any other foreign compound-metabolizing enzyme in humans. Recently, increasing evidence has been found showing that variants in the CYP3A4 gene have functional significance and--i …
Cytochrome P450 3A4 (CYP3A4) is involved in the metabolism of more drugs in clinical use than any other foreign compound-metabolizing enzyme …
Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.
Zanger UM, Schwab M. Zanger UM, et al. Pharmacol Ther. 2013 Apr;138(1):103-41. doi: 10.1016/j.pharmthera.2012.12.007. Epub 2013 Jan 16. Pharmacol Ther. 2013. PMID: 23333322 Free article. Review.
Cytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and response. Of 57 putatively functional human CYPs only about a dozen enzymes, belonging to the CYP1, 2, and 3 families, are responsible for the biotransformation of most foreign sub …
Cytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and response. Of 57 putatively functional human
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. de Man FM, et al. Clin Pharmacokinet. 2018 Oct;57(10):1229-1254. doi: 10.1007/s40262-018-0644-7. Clin Pharmacokinet. 2018. PMID: 29520731 Free PMC article. Review.
Irinotecan has a highly complex metabolism, including hydrolyzation by carboxylesterases to its active metabolite SN-38, which is 100- to 1000-fold more active compared with irinotecan itself. Several phase I and II enzymes, including cytochrome P450 (CYP) 3A4 and uridine …
Irinotecan has a highly complex metabolism, including hydrolyzation by carboxylesterases to its active metabolite SN-38, which is 100- to 10 …
Trends in Tramadol: Pharmacology, Metabolism, and Misuse.
Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R. Miotto K, et al. Anesth Analg. 2017 Jan;124(1):44-51. doi: 10.1213/ANE.0000000000001683. Anesth Analg. 2017. PMID: 27861439 Review.
The opioid analgesic potency of a given dose of tramadol is influenced by an individual's CYP genetics, with poor metabolizers experiencing little conversion to the active M1 opioid metabolite and individuals with a high metabolic profile, or ultra-metabolizers, exp …
The opioid analgesic potency of a given dose of tramadol is influenced by an individual's CYP genetics, with poor metabolizers …
Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review.
Stout SM, Cimino NM. Stout SM, et al. Drug Metab Rev. 2014 Feb;46(1):86-95. doi: 10.3109/03602532.2013.849268. Epub 2013 Oct 25. Drug Metab Rev. 2014. PMID: 24160757 Review.
CYP-450 enzymes may also contribute to the secondary metabolism of THC, and UDP-glucuronosyltransferases have been identified as capable of catalyzing both primary (CBD, CBN) and secondary (THC, JWH-018, JWH-073) cannabinoid metabolism. ...Studies of THC, CBD, and CBN inhi
CYP-450 enzymes may also contribute to the secondary metabolism of THC, and UDP-glucuronosyltransferases have been identified as capa
Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis.
Elfaki I, Mir R, Almutairi FM, Duhier FMA. Elfaki I, et al. Asian Pac J Cancer Prev. 2018 Aug 24;19(8):2057-2070. doi: 10.22034/APJCP.2018.19.8.2057. Asian Pac J Cancer Prev. 2018. PMID: 30139042 Free PMC article. Review.
Genetic polymorphisms of CYPs may affect the enzyme catalytic activity and have been reported among different populations to be associated with various diseases and adverse drug reactions. With regard of drug metabolism, phenotypes for CYP polymorphism range from ultrarapi …
Genetic polymorphisms of CYPs may affect the enzyme catalytic activity and have been reported among different populations to be associated w …
Duloxetine: clinical pharmacokinetics and drug interactions.
Knadler MP, Lobo E, Chappell J, Bergstrom R. Knadler MP, et al. Clin Pharmacokinet. 2011 May;50(5):281-94. doi: 10.2165/11539240-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21366359 Review.
Patient demographic characteristics found to influence the pharmacokinetics of duloxetine include sex, smoking status, age, ethnicity, cytochrome P450 (CYP) 2D6 genotype, hepatic function and renal function. Of these, only impaired hepatic function or severely impaired ren …
Patient demographic characteristics found to influence the pharmacokinetics of duloxetine include sex, smoking status, age, ethnicity, cytoc …
729 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page